Lupus Anticoagulant Blood Test in Lahore at Chughtai Lab

Lupus Anticoagulant at Chughtai Lab

The Lupus Anticoagulant test is a highly specialized coagulation profile investigation designed to detect the presence of antiphospholipid antibodies in the blood. Despite its potentially misleading name, the lupus anticoagulant is not a drug, nor is it exclusive to individuals diagnosed with Systemic Lupus Erythematosus (SLE). Furthermore, while it acts as an anticoagulant in laboratory test tubes (in vitro) by prolonging clotting times, inside the human body (in vivo), it is a powerful procoagulant that significantly increases the risk of inappropriate blood clot formation (thrombosis). At Chughtai Lab, Pakistan’s premier diagnostic network, this test is performed using advanced automated coagulation analyzers and standardized methodologies to ensure the highest degree of clinical accuracy and reliability.

Understanding the clinical significance of lupus anticoagulant is vital for patients experiencing unexplained arterial or venous thrombotic events, such as deep vein thrombosis (DVT), pulmonary embolism, or stroke. It is also a cornerstone diagnostic tool in the evaluation of recurrent pregnancy loss and obstetric complications. The test does not measure a single chemical entity; rather, it involves a multi-step testing cascade that includes screening, mixing, and confirmatory assays. This rigorous diagnostic pathway is essential because lupus anticoagulants are heterogeneous antibodies that interfere with phospholipid-dependent coagulation reactions. By choosing Chughtai Lab, patients benefit from a state-of-the-art laboratory infrastructure, expert hematologists, and a seamless testing experience designed to provide clear, actionable diagnostic insights.

The primary utility of the Lupus Anticoagulant test lies in its role as a diagnostic criterion for Antiphospholipid Syndrome (APS), an autoimmune disorder characterized by recurrent thrombosis and pregnancy morbidity. Because these antibodies can transiently appear during infections or as a result of certain medications, clinical guidelines require a positive result to be confirmed with a repeat test at least 12 weeks after the initial detection. Chughtai Lab provides comprehensive diagnostic support throughout this testing timeline, ensuring that longitudinal patient data is accurately tracked and reported to facilitate optimal clinical management by rheumatologists, hematologists, and obstetricians.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is absolutely critical for the accuracy of the Lupus Anticoagulant test, as several external factors, particularly medications, can interfere with the coagulation cascade and lead to false-positive or false-negative results. Patients must strictly adhere to the following preparation guidelines:

• Anticoagulant Therapy: The most critical preparation step is the temporary discontinuation of anticoagulant medications. Direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban, and dabigatran must typically be stopped for at least 48 hours prior to blood collection. Warfarin (Coumadin) therapy should ideally be discontinued or transitioned to low-molecular-weight heparin (LMWH) for 1 to 2 weeks before the test, under the strict supervision of the prescribing physician. Heparin therapy should also be paused as directed by your doctor, as heparin contamination can significantly prolong clotting times and mimic the presence of a lupus anticoagulant.
• Fasting Requirements: While strict fasting is generally not mandatory for a standalone Lupus Anticoagulant test, patients are advised to avoid high-fat meals for at least 4 to 6 hours before the blood draw. Lipemic (fatty) blood samples can interfere with the optical detection systems used by automated coagulation analyzers, potentially compromising the test results.
• Hydration: Staying well-hydrated by drinking plenty of water is highly recommended. Adequate hydration makes the veins more accessible, facilitating a smoother and quicker venipuncture process.
• Medical History Disclosure: Always inform the laboratory staff and your healthcare provider about all prescription medications, over-the-counter drugs, herbal supplements, and recent infections, as these can influence your immune and coagulation profiles.

During the Procedure

The blood collection process for the Lupus Anticoagulant test at Chughtai Lab is performed by highly trained phlebotomists who adhere to strict international standards of patient safety and sample integrity. The procedure is quick, minimally invasive, and follows a standardized protocol:

• Patient Positioning: You will be asked to sit comfortably in a specialized phlebotomy chair. The phlebotomist will locate a suitable vein, typically in the antecubital fossa (the inner bend of your elbow).
• Sanitization and Tourniquet Application: A tourniquet is applied to your upper arm to increase venous pressure and make the vein more visible. The phlebotomist will thoroughly sanitize the skin at the puncture site using an antiseptic swab to prevent any contamination.
• Venipuncture: A sterile, single-use needle is gently inserted into the vein. You may feel a brief, mild pinch or stinging sensation. The blood is drawn directly into a light blue-top tube containing buffered sodium citrate. The sodium citrate acts as a reversible anticoagulant that preserves the clotting factors in your plasma for precise laboratory analysis.
• Tube Filling and Mixing: It is clinically vital that the collection tube is filled to its exact designated capacity to maintain the precise 9:1 ratio of blood to sodium citrate. An incorrect ratio can falsely prolong clotting times. Immediately after drawing, the tube is gently inverted several times to ensure thorough mixing of the blood with the anticoagulant.
• Post-Draw Care: Once the sample is collected, the needle is removed, and a sterile cotton ball or gauze pad is pressed onto the site to stop any bleeding. A small adhesive bandage is applied, and you will be advised to keep pressure on the site for a few minutes.
• Sample Processing: At Chughtai Lab, the blood sample undergoes double centrifugation within a specified timeframe to obtain platelet-poor plasma (PPP). This step is crucial because platelets contain phospholipids that can neutralize lupus anticoagulants during freezing or testing, leading to false-negative results.

When is a Lupus Anticoagulant Test Performed?

Investigation of Unexplained Venous or Arterial Thrombosis

Physicians frequently request a Lupus Anticoagulant test when a patient presents with unexplained blood clots, particularly at a young age (under 50 years) or in unusual anatomical locations. Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) in the legs and pulmonary embolism (PE) in the lungs, can cause severe symptoms like localized pain, swelling, warmth, shortness of breath, and chest pain. Arterial thrombosis can lead to stroke, transient ischemic attacks (TIAs), or myocardial infarction. When these life-threatening events occur without obvious risk factors, such as major surgery or prolonged immobility, a Lupus Anticoagulant test helps determine if an underlying autoimmune hypercoagulable state is the primary cause.

Evaluation of Recurrent Pregnancy Loss and Obstetric Complications

Recurrent pregnancy loss is a devastating condition defined as multiple consecutive, unexplained miscarriages. Antiphospholipid antibodies, including lupus anticoagulant, can cause placental thrombosis, leading to placental insufficiency, fetal growth restriction, pre-eclampsia, and early-term pregnancy loss. Obstetricians routinely order this test for women who have experienced three or more unexplained consecutive miscarriages before the 10th week of gestation, one or more unexplained fetal deaths at or beyond the 10th week, or premature births before the 34th week due to severe pre-eclampsia or placental dysfunction. Identifying the presence of lupus anticoagulant allows specialists to initiate appropriate preventative therapies, such as low-dose aspirin and heparin, to improve pregnancy outcomes.

Investigation of an Unexplained Prolonged Activated Partial Thromboplastin Time (aPTT)

An activated partial thromboplastin time (aPTT) test is a routine screening investigation used to evaluate the intrinsic pathway of coagulation, often performed before major surgical procedures. Occasionally, an otherwise healthy patient without a history of bleeding or clotting may present with an incidentally discovered, unexplained prolonged aPTT. Because lupus anticoagulant antibodies bind to the phospholipids used in the aPTT reagent, they interfere with the test and artificially prolong the clotting time. When a prolonged aPTT does not correct during a mixing study (where the patient’s plasma is mixed with normal plasma), a Lupus Anticoagulant test is indicated to confirm whether the prolongation is due to these specific antibodies rather than a clotting factor deficiency.

Diagnosis and Classification of Antiphospholipid Syndrome (APS)

Antiphospholipid Syndrome (APS) is a systemic autoimmune disorder characterized by clinical features of thrombosis or pregnancy complications combined with persistent laboratory evidence of antiphospholipid antibodies. The Lupus Anticoagulant test is one of the three primary laboratory assays used to diagnose APS, alongside anticardiolipin antibodies and anti-beta-2 glycoprotein I antibodies. Because transient antibodies can appear due to infections, clinical guidelines dictate that a positive lupus anticoagulant result must be confirmed by repeat testing after a minimum of 12 weeks. Establishing a definitive diagnosis of APS is crucial, as it dictates long-term, often lifelong, anticoagulant management to prevent recurrent thromboembolic events.

Monitoring and Risk Assessment in Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus (SLE) is a chronic multisystem autoimmune disease that can affect almost any organ system. Approximately 10% to 30% of patients diagnosed with SLE also test positive for lupus anticoagulant antibodies. While not all patients with these antibodies will develop blood clots, their presence significantly increases the lifetime risk of thrombotic complications. Rheumatologists routinely perform Lupus Anticoagulant testing in SLE patients to stratify their cardiovascular and thrombotic risk, guide prophylactic treatment strategies during high-risk periods (such as surgery or pregnancy), and monitor the overall progression and activity of the autoimmune disease.

What Does a Lupus Anticoagulant Test Detect?

The Lupus Anticoagulant test is a comprehensive diagnostic panel that evaluates several parameters within the coagulation cascade. Rather than detecting a single molecule, it identifies the presence and functional impact of phospholipid-dependent inhibitors. The test systematically detects, confirms, and evaluates the following clinical aspects:

• Presence of circulating lupus anticoagulant immunoglobulins (IgG and IgM).
• Prolongation of phospholipid-dependent clotting times in screening assays.
• Dilute Russell’s Viper Venom Time (dRVVT) screening abnormalities.
• Silica Clotting Time (SCT) screening abnormalities.
• Lupus anticoagulant-sensitive activated partial thromboplastin time (aPTT-LA) prolongation.
• Failure of prolonged clotting times to correct during a 1:1 mixing study with normal pooled plasma, indicating the presence of an inhibitor rather than a factor deficiency.
• Correction of prolonged clotting times upon the addition of excess phospholipids, confirming the phospholipid-dependent nature of the inhibitor.
• Differentiating between specific factor inhibitors (such as Factor VIII inhibitors) and non-specific lupus anticoagulants.
• Assessment of the patient’s overall hypercoagulable state and thrombotic risk profile.
• Evaluation of potential causes for recurrent, unexplained first-trimester miscarriages.
• Identification of risk factors for late-term unexplained fetal demise.
• Detection of transient lupus anticoagulant antibodies associated with viral or bacterial infections.
• Identification of drug-induced lupus anticoagulants caused by medications like procainamide, hydralazine, or quinidine.
• Evaluation of placental vascular thrombosis risk in pregnant patients.
• Assessment of venous thromboembolism (VTE) risk, including deep vein thrombosis and pulmonary embolism.
• Assessment of arterial thrombosis risk, including ischemic stroke and myocardial infarction.
• Presence of co-existing antiphospholipid antibodies when combined with anticardiolipin and anti-beta-2 glycoprotein I assays.
• Baseline coagulation status prior to the initiation of long-term anticoagulant therapy.
• Exclusion of heparin contamination in the blood sample using heparin-neutralizing agents.
• Confirmation of persistent antiphospholipid antibodies through serial testing performed 12 weeks apart.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, we understand that waiting for diagnostic results can be an anxious time for patients and their families. Because the Lupus Anticoagulant test is a highly specialized, multi-step coagulation assay requiring precise laboratory processing and expert interpretation by consultant hematologists, the turnaround time is typically within 24 to 48 hours from the time of sample collection. This ensures that every sample undergoes the necessary screening, mixing, and confirmatory testing without compromising on clinical accuracy.

Chughtai Lab offers multiple convenient methods for patients to access their diagnostic reports. Once your report is finalized and signed off by our consultant pathologist, you will receive an automated SMS notification on your registered mobile number. You can instantly view and download your secure PDF report via the official Chughtai Lab website or the user-friendly Chughtai Lab mobile application. Additionally, physical copies of the report can be collected from any of our numerous diagnostic centers and collection points located conveniently across Lahore and other major cities in Pakistan. Our digital reporting system ensures that your medical records are securely archived and easily accessible whenever you or your treating physician need them.

Lupus Anticoagulant Findings Overview

The interpretation of a Lupus Anticoagulant panel involves analyzing multiple ratios and clotting times. The table below outlines the key parameters evaluated during the testing process, along with their normal and abnormal clinical implications:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
dRVVT Screen Ratio	Ratio < 1.2 (Normal clotting time)	Ratio ≥ 1.2 (Prolonged clotting time, suggesting the presence of an inhibitor)
dRVVT Confirm Ratio	Correction of clotting time with excess phospholipid	Failure to correct completely (may indicate a strong inhibitor or factor deficiency)
dRVVT Screen/Confirm Ratio	Ratio < 1.2 (Negative for lupus anticoagulant)	Ratio ≥ 1.2 (Positive, confirming the presence of a phospholipid-dependent lupus anticoagulant)
Silica Clotting Time (SCT) Screen	Clotting time within established reference range	Prolonged clotting time (indicates potential presence of lupus anticoagulant)
SCT Confirm Ratio	Ratio < 1.16 (Negative for lupus anticoagulant)	Ratio ≥ 1.16 (Positive, confirming phospholipid-dependent inhibition)
1:1 Mixing Study (aPTT or dRVVT)	Correction of prolonged clotting time to within normal range	Failure to correct clotting time (confirms the presence of a circulating inhibitor)
Platelet Neutralization Procedure	Negative (No significant shortening of clotting time)	Positive (Significant shortening of clotting time, confirming lupus anticoagulant)
Thrombin Time (TT) / Reptilase Time	Normal clotting times (rules out heparin contamination)	Prolonged TT with normal Reptilase Time (indicates therapeutic heparin contamination in the sample)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Lupus Anticoagulant Testing?

• Experienced Healthcare Professionals: Our hematology department is led by highly qualified consultant pathologists and hematologists with extensive experience in diagnosing complex coagulation disorders.
• State-of-the-Art Diagnostic Equipment: Chughtai Lab utilizes fully automated, high-throughput coagulation analyzers that ensure precise, standardized, and reproducible test results.
• Accurate and Reliable Reporting: We adhere to strict internal quality control measures and participate in international external quality assurance programs to maintain the highest diagnostic standards.
• Convenient Home Sampling Services: Patients can schedule a professional phlebotomist to collect blood samples from the comfort of their homes across Lahore and other major cities.
• Easy Access to Digital Reports: Retrieve your diagnostic reports instantly through our secure online portal, mobile app, or via direct SMS links.
• Extensive Nationwide Network: With hundreds of collection centers across Pakistan, accessing world-class diagnostic services is convenient and hassle-free.
• Patient-Focused Care: We prioritize patient comfort, safety, and confidentiality at every stage of the diagnostic journey.
• Comprehensive Diagnostic Approach: Chughtai Lab offers a complete range of complementary tests, including anticardiolipin and anti-beta-2 glycoprotein I antibodies, for a thorough Antiphospholipid Syndrome evaluation.